Print This Page
Share this page: More

Zilver PTX

Summary of Trial: 
This investigation will compare the long-term (12-month) safety and effectiveness of the Zilver® PTX™ Drug-Eluting Vascular Stent to Control (PTA) in a multicenter clinical trial involving up to 56 investigative sites.

Patients with de novo or restenotic lesions of the above-the-knee femoropopliteal artery that have not been previously stented will be eligible to be randomly assigned to either the Zilver® PTX™ Drug-Eluting Vascular Stent group or the Control group. A single lesion in each limb (total of two lesions per patient) may be treated.

Results from this study will be used to evaluate the short-term (1 year) primary study outcome which is needed to evaluate safety and performance of this device and to support submission of marketing approval. When the last enrolled patient completes 1-year follow-up, a regulatory submission for marketing approval (e.g., Shonin and PMA) will be prepared. Longer term (5-year) follow-up data will be collected to provide valuable information on late adverse events and device integrity.

Principal Investigator:Mahmoud B Malas, M.D., MHS, FACS
Study Coordinator:

Umair Qazi, M.D., MPH

Study Long Title: 

Evaluation of the Zilver PTX TM Vascular Stent in the Above-the-Knee Femoropopliteal Artery Clinical Study Protocol

Study Short Title: Zilver PTX
JHU IRB Number:


Funding Source:Cook Incorporated
Clinical Trial Site: The study enrolled patients in multiple sites across the U.S. Enrollment is now closed. Patients are in currently in follow-up. 

Johns Hopkins Bayview Medical Center
4940 Eastern Ave
Baltimore MD 21224
Start Date:2007
Anticipated End Date:2012
Compensation for Participating: None